Sub-study of Belantamab Mafodotin (GSK2857916) in Combination with Isatuximab in Participants with RRMM

Trial Identifier: 208887 Sub Study 5
Sponsor: GlaxoSmithKline
Start Date: July 2021
Primary Completion Date: April 2025
Study Completion Date: March 2027
Condition: Myeloma

Trial Locations

Country Location
Australia, VIC Fitzroy, VIC, Australia, 3065
Brazil, Bahia Salvador, Bahia, Brazil, 41253-190
Brazil, Sao Paulo Sao Paulo, Brazil, 04537-080
Canada, Ontario Toronto, Ontario, Canada, M5G 2M9
France VILLEJUIF CEDEX, France, 94805
Greece, NA Athens, NA, Greece, 11528
Korea, Republic of Seoul, Korea, Republic of, 06351
Korea, Republic of Seoul, Korea, Republic of, 06591
Korea, Republic of Ulsan, Korea, Republic of, 44033
Mexico, Mexico City Mexico City, Mexico, 01330
Norway Oslo, Norway, 0450
Spain Madrid, Spain, 28041
Spain Madrid, Spain, 28040
Spain Pozuelo de AlarcOn Madr, Spain, 28223
Sweden FALUN, Sweden, SE-791 82
United States, GA Atlanta, GA, United States, 30322
United States, MA Boston, MA, United States, 02215
United States, MI Grand Rapids, MI, United States, 49546
United States, WI Madison, WI, United States, 53792